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ABSTRACT
Purpose: In patients with massive ascites, large volume paracentesis may be associated with complications 
as circulatory dysfunction. Selection of appropriate patients might reduce such side effects. Patients and 
Methods: Forty-ﬁ  ve patients known to have liver cirrhosis and presenting with massive ascites were included. 
There were 27 males and 18 females, with age (mean 51.2+10.64). All patients were subjected to full history, 
clinical examination, complete blood picture, prothrombin time, serum albumin, total plasma protein, serum 
bilirubin, serum creatinine, serum electrolytes and plasma renin activity measured by radioimmunoassay. 
Echocardiographic evaluation for cardiac output, pulmonary artery pressure, diastolic and systolic function 
before and after paracentesis. Large-volume paracentesis (LVP) ranging 8–18 liters with a mean 9.9 L was 
performed to all patients. Paracentesis induced circulatory dysfunction (PICD) was deﬁ  ned as increase in plasma 
renin activity (PRA) of more than 50% of pretreatment value to a level greater than 7.5ng /ml/ hour on the 6th 
day after paracentesis. Results: The incidence of PICD in patients with massive hepatic ascites was 73.3% 
(87.5% with Dextran and 38.5% with albumin). There were no serious systemic or local side effects one week 
following LVP. Type of plasma expander and younger ages were the only independent predictors (odd ratio 
OR with 95% conﬁ  dence interval CI, 3.01<21.79<157.58 and 0.80<.88<.97 respectively) Gender and other 
clinical and laboratory parameters had no inﬂ  uence. Neither electrolytes levels nor hematocrite value had an 
inﬂ  uence. Ascitic patients showed higher heart rate and cardiac output and lower arterial pressure that was 
accentuated after LVP (P < 0.01). Echocardiographic diastolic function, A wave velocity and deceleration time 
of the E wave were markedly increased in cirrhotic patients with tense ascites and the E/A ratio was markedly 
reduced (0.9 ± 0.3) but was not signiﬁ  cantly affected by LVP. Ejection fraction had similar values of the normal 
patients with a tendency to increase after paracentesis. There were no changes in the left ventricular wall 
thickness. Conclusion: LVP is a safe and effective procedure for treatment of tense/refractory ascites. PICD 
is a frequently occurring silent complication following LVP. Salt free human albumin should be the plasma 
expander of choice especially if at least 8 liters are evacuated. Left ventricular diastolic function is altered in 
cirrhosis with tense ascites. This may represent an early stage of hepatic cardiomyopathy but was not affected 
by LVP and this was not reﬂ  ected on the occurrence of PICD.
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INTRODUCTION
Ascites is the most common of the three major complications 
of cirrhosis together with hepatic encephalopathy and 
variceal hemorrhage. The development of ﬂ  uid retention 
in the setting of cirrhosis is an important landmark in the 
natural history of chronic liver disease. Approximately 
50% of patients with compensated cirrhosis, develop 
ascites during 10 years of observation[1] and 50% of them 
succumb in two years,[2] which has led to the inclusion of 
ascites as one of the indications for initiating evaluation 
for liver transplantation.[3] 
Educations regarding dietary sodium restriction and oral Nasr, et al.: Circulatory dysfunction in massive hepatic ascites
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diuretics have long been the mainstays of treatment of 
patients with cirrhosis and ascites.[4,5] This approach, has 
been shown to be effective in 90% of patients, however 
10% lack response to high doses of diuretics or have 
recurrent side effects, (e.g., hepatic encephalopathy, 
hyponatremia, hyperkalemia, or azotemia) even when 
lower doses are given, and they are deﬁ  ned as having 
refractory Ascites.[6,7] 
Current therapeutic strategies for refractory ascites 
include repeated large-volume paracentesis (LVP) with 
the use of plasma expanders and transjugular intrahepatic 
portosystemic shunts (TIPS).[8,9] Comparisons with 
administration of diuretics at increasing doses (maximal 
doses, 400mg of spironolactone per day and 160mg of 
furosemide per day) until loss of ascetic ﬂ  uid is achieved, 
favors paracentesis as the method of choice,[7,10] because 
it is faster, more effective and is associated with fewer 
adverse events than diuretic therapy.[11-13] 
Although TIPS is effective and prevents recurrence in 
patients with refractory ascites[9,14] the disadvantages 
of this technique which include recurrence of ascites, 
hepatic encephalopathy, high cost and lack of availability 
in some centers limit its use.[15-18] Recently the Consensus 
Conference of the International Ascites Club has 
recommended that gross ascites should be treated with 
therapeutic paracentesis followed by colloid volume 
expansion, and diuretic therapy, and that repeated LVP 
may be the ﬁ  rst line treatment of refractory ascites.[19] 
However, the removal of large amounts of ascitic ﬂ  uid 
may induce an impairment of circulatory function that has 
been termed paracentesis-induced circulatory dysfunction 
(PICD), ﬁ  rst described by Gines et al, 1988.[20] This is a 
hyperdynamic state that can appear up to 6 days after the 
paracentesis and is related to marked activation of the 
renin-angiotensin system.[21,22] It is associated with a rapid 
return of ascites, renal failure, and a worsened prognosis 
and may require medical intervention and frequent 
hospitalization.[23] Moreover, PICD is not spontaneously 
reversible and patients who develop this disorder show a 
reduced survival.[24]
The objectives of the present study were:
1.  To estimate the rate of PICD after LVP in cirrhotic 
patients with tense/refractory ascites.
2.  To identify the pretreatment predictors that may allow 
the selection of the most appropriate candidate for 
large volume paracentesis.
3.  To asses the clinical and hemodynamic changes 
associated with LVP and their relation with PICD.
PATIENTS AND METHODS
Study design
This study was conducted as a comparative study of 
cirrhotic patients with massive ascites before and after 
large-volume paracentesis
Patients
Inclusion criteria
1.  Consecutive patients attending at Suez Canal University 
Hospital with liver cirrhosis based on clinical, 
laboratory data and ultrasonographic ﬁ  ndings. 
2.  Tense ascites not responding to maximum dose of 
diuretics after at least 4 weeks of treatment.
3.  Patients of both gender with an age above 20 years.
4.  Consent of the patient.
Exclusion criteria 
1.  Respiratory, cardiac or renal failure 
2.  Noncirrhotic ascites as tuberculosis, peritoneal 
carcinomatosis
3.  Active gastrointestinal bleeding or history in the 
preceding month 
4.  Spontaneous bacterial peritonitis and hepatic 
encephalopathy grade 2 or more
5.  Evidence of hepatocellular carcinoma
6. Treatment  with  β-blockers for prophylaxis of variceal 
bleeding
7.  Systemic sepsis within the past month
8.  Platelet count less than 30˜103 /mm3
9.  Prothrombin concentration less than 30% 
Outcome factor
PICD was deﬁ  ned as increase in plasma renin activity 
(PRA) of more than 50% of pretreatment value to 
level greater than 7.5 ng /ml/ hour on the 6th day after 
paracentesis Gines et al, 1996[24] 
Prognostic factors
Age, sex, severity of liver disease (Child–Pugh grade), co-
morbid conditions (DM, HTN, IHD), electrolytes (sodium 
and potassium), Creatinine level, Plasma expander given 
(dextran 70 or human albumin), and amount of ﬂ  uid 
aspirated. 
Methods
Elligible patients from the outpatient clinic or emergency 
department were admitted to the hospital until at least 
one week after paracentesis. During hospital stay patients 
received adequate treatment according to their condition 
including low salt diet and diuretics.Nasr, et al.: Circulatory dysfunction in massive hepatic ascites
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All patients were subjected to the following:
History and physical examination: including vital signs, 
general signs of liver failure, assessment for encephalopathy, 
cardiac and abdominal examination. 
Laboratory investigations: including: Complete blood 
picture, ALT and AST, serum albumin, serum bilirubin, 
PT, serum creatinine, serum electrolytes (Na and K), 
random blood sugar and PRA. All samples for laboratory 
tests were collected immediately before and at 6th days 
after paracentesis
The routine hematological and biochemical studies were 
performed using standard laboratory techniques. 
Samples for PRA were obtained through a catheter inserted 
in a peripheral vein with the patient lying supine and rested 
in bed for an adequate time. The samples were collected 
at room temperature in tubes containing EDTA-K and 
immediately centrifuged. The plasma obtained was then 
frozen (-30°C) until analyzed. PRA was measured by a 
commercial kit to estimate the generation of angiotensin 
1 by radioimmunoassay. The normal value for PRA was 
4.5- 7.5ng/ml/hour 
Abdominal ultrasonography: was performed before the 
paracentesis using the HITACHI EUB 200 machine with 
linear probe.
2 D-Doppler echocardiography: Echocardiographic 
evaluation was performed before and on the 2nd day 
after paracentesis using a Hewlett-Packard phased array 
(Sons 1800, USA made, model: DR 53 15) ultrasonoscope 
using a 2.5 and 3.5 MHz phased array transducer probe 
using the left parasternal view (M- Mode and the apical 
four- chamber subcostal view (B-Mode) according to the 
American Society of echocardiography convention. In the 
apical four–chamber view a doppler recording of diastolic 
mitral ﬂ  ow was obtained by positioning the sample volume 
on the inﬂ  ow area of the left ventricle just below the level 
of the mitral annulus. Measurements obtained were cardiac 
output, pulmonary artery pressure, wall thickness (left 
ventricular posterior wall thickness and inter ventricular 
septum thickness) left ventricular systolic, diastolic function 
and other cardiac abnormalities. Measurements derived 
from at least three cardiac cycles were averaged. The systolic 
function was evaluated by the ejection fraction of the left 
ventricle while diastolic function was evaluated by E /A ratio. 
Large volume paracentesis: was performed on the 
second day of admission as described in detail by Tito et 
al, 1990.[25] An 18 – 16 g cannula with an inner sharp metal 
needle was inserted under strict aseptic conditions in the 
left lower abdominal quadrant. Once the needle entered the 
peritoneal cavity, the inner part was removed and ascetic 
ﬂ  uid was drained into a sterile container. The process 
continued till at least 8 L - and short of total paraceentesis 
- were drained over a 2 hours period. 
Intravenous infusion of Dextran70 6% was given during 
the paracentesis (100 C.C per each liter of ascitic ﬂ  uid 
removed) or Salt-Free Human Albumin (SFHA) (8g\L 
per each liter of ascetic ﬂ  uid removed, 50% of the dose 
within the ﬁ  rst 2 hours and 50% 8 hours after paracentesis).
Fresh frozen plasma was given for patients with prolonged 
prothrombin time, and Platelets transfusion was given to 
patients with thrombocytopenia (below 40.000/c.c.)
Statistical analysis
Descriptive statistical methods were used for data analysis 
and results were expressed as range or means with standard 
deviation (mean ± SD). Differences between groups were 
assessed by using parametric tests, continuous variables 
were assessed by using paired T test or Kruskl-Wallis 
test (if the variance was not homogenous) Qualitative 
variables were presented as frequencies, and differences 
were assessed by using Chi square (χ2)-Mc Nemur test. The 
level of statistical signiﬁ  cance was set at P < 0.05. A best 
ﬁ  tting logistic regression model was done to identify the 
independant predictors of PICD from all the signiﬁ  cant 
different variables by univariate analysis. 
RESULTS
Forty ﬁ  ve patients presenting with massive cirrhotic ascites 
who were consecutively admitted to the hospital were 
included in the study. The baseline demographic, clinical 
and laboratory characteristics of the study patients are 
presented in Table 1. They were 27 males (60%) and 18 
females (40%), and their ages ranged between 26 and 79 
years (mean 51.2 ± 10.64). Cirrhosis was due to chronic 
virus C hepatitis in the vast majority of cases and only a few 
had HBV or combined infection and none gave history of 
alcoholism. Jaundice was present in 29 (64%), peripheral 
edema in 37 (82%) and bleeding tendency (epistaxis /
bleeding gums) in 5 (11.1%). Hypertension and Diabetes 
Mellitus was present in 7 (15.6%) and 9 (20%) respectively 
and Grade 1 encephalopathy was present in 6 (13.3%). 
The mean value of Hb (mean 9.93 ± 1.84), hamatocrit 
(mean 29.3 ± 5.6) and platelets count (mean 124 ± 77) Nasr, et al.: Circulatory dysfunction in massive hepatic ascites
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were lower than normal. S albumin (mean2.03 ± 0.46) was 
also decreased while serum bilirubin (mean 2.033 ± 1.67) 
was elevated and PT (mean 14.99 ± 2.44) was prolonged. 
S. creatinine (mean 1.35 ± 0.87), S. Na (mean 134.1 ± 9.4) 
and S. K (4.3 ± 0.68) and random blood sugar (mean 142.8 
± 104.9) were within normal levels. It is worth mentioning 
that all the study subjects were classiﬁ  ed as Child –Pugh 
class C according to the clinical and laboratory ﬁ  ndings.
Table 2 describes the pertinent ultrasonographic ﬁ  ndings 
in the study subjects. As expected most of the cases had a 
shrunken liver (60%) while only 24.4% had hepatomegaly. 
The portal vein was dilated in 55.6% of cases (mean 13.4 ± 
1.4mm). The spleen was also enlarged in most cases (mean 
15.5 ± 5.2cm) and the splenic vein was dilated in 60.0% of 
cases (mean 10.05 ± 4.3mm).
The paracentesis procedure events, PRA before and after, 
and the frequency of PICD in the total study subjects and 
outcome groups are presented in Table 3. Paracentesis was 
done after 24 hours of admission for each patient. The 
volume of ﬂ  uid aspirated ranged between 8 and 18 liters 
(mean 9.9 ± 4.0). The plasma expander used was Dextran 
in 32 (71.1%) and Albumin in 13 (28.9%) of patients. The 
mean PRA increased from 8.3 ± 6.3 ng/l/hr before to 
18.3 ± 10.3 after paracentesis and PICD occurred in 33 
(73.3%) of patients.
Accordingly the patients were classiﬁ  ed into the 2 outcome 
groups; with and without PICD. As shown in Table 3 
there was no signiﬁ  cant difference in mean volume of 
aspirated ﬂ  uid between the 2 groups. However, there was 
a highly signiﬁ  cant statistical difference in the type of 
plasma expander used between them (P = 0.002). Out of 
the patients who received Dextran, 28/32 patients (87.5%) 
developed PICD representing 84.8% of this group. While 
only 4/32 (12.5%) who received it did not develop PICD 
representing 33.3%. of this group. On the other hand 5/13 
patients (38.5%) who received albumin developed PICD 
and 8/15 (66.7%) did not, representing 15.2% and 66.7% 
of their respective groups. 
Although PRA was slightly higher at baseline among 
the group that developed PICD, the difference was not 
statistically signiﬁ  cant. The mean PRA increased from 8.98 
± 5.22 to 23.97 ± 6.62 in those who developed PICD and 
only from 7.27 ± 7.85 to 9.09 ± 8.59 in those who did not 
and the difference post paracentesis was highly statistically 
signiﬁ  cant (P < 0.001). 
Comparison of the possible risk factors of PICD between 
the outcome groups is shown in Table 4 and Table 5. 
The mean age was signiﬁ  cantly lower among those who 
developed PICD (48.8 ± 9.6) than those who did not (57.8 
± 10.9). There was no signiﬁ  cant difference between the 
2 groups as regards gender or clinical variables except 
diabetes mellitus which was signiﬁ  cantly more frequent 
among those who did not develop PICD [Table 4]. 
Table 1: Demographic, clinical and laboratory 
characteristics of patients with massive cirrhotic 
ascites
Demographic, clinical and 
laboratory variables
Value
Gender
Male                                                27 (60%)
Female 18 (40%)
Age (in years)
<40 5  (11.1)
41-50 18  (40)
> 51 22 (48.9)
Mean                     51.2 ± 10.6
Jaundice                                                    29 (64.4)
Peripheral edema                                     37 (82.2)
Bleeding tendency                                    5 (11.1)
Heart rate (bpm)                                            87.5 ± 8.3
Hypertension                                            7 (15.6)
Arterial blood pressure (mmHG)                      98.4 ± 20.8
Diabetes Mellitus                                     9 (20)
Encephalopathy - grade <2                    6 (13.3)
Hemoglobin   g/dL                                          9.93 ± 1.83
Hematocrit                                              29.34 ± 5.57
Leucocytic count ×103//mm3                           6.7 ± 3.5
Platelet count ×103//mm                                   124.0 ± 77.02
Random blood sugar mg/dL                            142.89 ± 104.94
S. Bilirubin – total mg/dL                                2.03 ± 1.67
S. Albumin  g/dL                                          2.22 ± 0,46
Internation normalized ratio  (INR)      1.3 ± 0.3
S.Creatinine mg/dL                                            1. 35 ± 0.87
S. Sodium meq/L                                                134.1 ± 9.4
S. Potassium meq/l                                            4.3 ± 0.7
Child- Pugh Class C                                     45 (100)
Data are expressed as No (%) and mean ± SD
Table 2: Ultrasound ﬁ  ndings of the  patients with 
massive cirrhotic ascites 
Ultrasound ﬁ  ndings Character
Liver: 
Normal 7 (15.5)
Enlarged 11 (24.4)
Shrunken 27 (60.0)
Dilated portal vein (mm)  25 (55.6)
Diameter    13.4 ± 1.4
Range 7 – 22
Spleen size (cm)  15.54 ± 5.2
Range 10 - 42
Dilated splenic vein  27 (60.0)
Diameter (mm)  10.05 ± 4.3
Range 4.0 – 18.0
Data are expressed as No (%) and mean ± SDNasr, et al.: Circulatory dysfunction in massive hepatic ascites
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Similarly, there was no signiﬁ  cant differences between 
hematological, biochemical and electrolyte laboratory 
variables among those who developed PICD and those 
who did not, except for the mean random blood glucose 
which was signiﬁ  cantly higher among those who did not 
develop PID (188.4 ± 111.9) than those who did (123.5 
± 98.0) [Table 5].
The best ﬁ  tting stepwise logistic regression model for 
occurrence of circulatory dysfunction as a dependant 
variable, verses various personal and disease characteristics 
as independent variables [Table 6], has identiﬁ  ed younger 
age and Dextran (type of plasma expander used) as the 
only independent signiﬁ  cant risk factors with OR and 
95% CI (0.88, 0.80 – 0.97) for the former and (21.79, 3.01 
– 157.58) for the latter. The 2 variables explained 51% of 
the model (R-square = 0.51) which was highly statistically 
signiﬁ  cant (P < 0.0001).
The haemodynamic status of the study patients before 
LVP (at base line) and 48 hours after are shown in Table 7. 
At base line the mean heart rate (HR) (87.5 ± 8.3) and 
cardiac output (COP) (7.5 ± 1.9) were higher than the 
normal range, while mean arterial pressure (98.4 ± 20.8) 
was lower than normal,. The ejection fraction (EF) (58.7 ± 
9.99), the posterior wall thickness (PwT0) (1.0 ± 0.2) and 
inter ventricular wall thickness (IVwT) (1.0 ± 0.2) were 
within normal limits. The EA ratio (0.9 ± 0.3) was lower 
than normal values and pulmonary artery pressure (PAP) 
(31.7 ± 15.2) was markedly increased. Forty eight hours 
after LVP there was signiﬁ  cant increase in HR to (95.5 
± 9.5) and COP to (8.3 ± 2.3) and signiﬁ  cant decrease in 
MAP to (90.7 ± 14.4). On the other hand there was no 
signiﬁ  cant change in EF, EA ratio, PAP or PwT and IVwT. 
Table 8 shows comparison between those who developed 
PICD and those who did not as regards hemodynamic 
status at base line, 48 hours post-LVP and the mean 
before/after change. There was no statistically signiﬁ  cant 
difference in haemodynamic parameters between the 
2 groups before or after LVP except HR and IVwT 
which were signiﬁ  cantly slightly higher among those 
who did not develop PICD only at base line (P = 0.03 
and 0.04 respectively). The HR increased (8.3 ± 0.97 
and 6.92 ± 1.57 respectively, P = 0.001 for both) and 
COP increased (0.9 ± 0.22, P =0.001 and 0.88 ± 0.37, P 
=0.38 respectively) and MAP decreased (-8.38 ± 2.6, P 
=0.002 and -6.42 ± 3.22, P = 0.071 respectively). There 
was no signiﬁ  cant change in the other echcardiographic 
parameters namely: EF, E/A ratio, PAP, PwT or IVwT 
among the 2 groups. 
Table 3: Descriptive data of paracentesis procedure 
and frequency of PICD for the patients  
Variable Total PICD 
(n=33)
No PICD 
(n=12)
P 
value
Aspirated volume - Liter
Range  8.0 - 28
9.9 ± 4.0
8.0 - 28.0
10.4 ± 4.6
8.0 -10.0
8.5 ± 0.7
 0.09
Plasma expander used 
Albumin 13 (28.9) 5 (15.20) 8 (66.7) 0.002*
Dextran 32 (71.1) 28 (84.8) 4 (33.3)
Plasma rennin activity (ng/ml/h)
Before 8.3 ± 6.3 8.98 ± 5.22 7.27 ± 7.85 0.43
After 18.3 ± 10.3 23.97 ± 6.62 9.09 ± 8.59 <001*
PICD N (%) 33 (73.3) 33 (100) -------
Data are expressed as No (%) and mean ± SD  PICD = paracentesis induced 
circulatory disfunction * = signiﬁ  cant
Table 4: Comparison of demographic and clinical data 
between those who developed PI CD and those who 
did not
Variable PICD 
(n=33)
No PICD 
(n=12)
P  
value
Age 48.8 ± 9.6 57.8 ± 10.9 0.01*
Range 26 – 70 41 - 79
Gender
Females 12 (36.4) 6 (50.0)  0.50
Male 21 (63.6) 6 (50.0)
Jaundice  6 (18.2) 4 (33.3) 0.42
Perﬁ  ral edema  26 (78.8) 11 (91.70 0.42
Hear rate (b/m) SD 89. 0 ± 8.0 92.5 ± 7.8  0.19
Hypertension  4 (12.1) 3 (25.0)  0.36
Arterial BP  98.5 ± 17.9 98.3 ± 23.7  0.98
Diabetes mellitus  4 (12.1) 5 (41.70 0.04*
Encephalopath  grade <2 4 (12.1) 2 (16.7) 0.65
Data are expressed as No (%) and mean ± SD  * = Signiﬁ  cant
Table 5: Comparison of laboratory ﬁ  ndings between 
those who developed PICD and those who did not
Variable PICD 
(n=33)
N0 PICD 
(n=12)
P 
value
Hemoglobin    g/dL                                          9.8  ±  2.0 10.0  ±  1.6 0.78
Hematocrit 29.7 ±5.7 30.2 ± 5.0 0.81
Leucocytic count ˜10³/
mm
6.36 ± 3.42 7.46 ± 3.71 0.32
Platelet count ˜10³/mm³ 122.9 ± 66.4 127.0 ± 104.4 0.52
Random blood sugar 
mg/dl
123.5 ± 98.0 188.4 ± 111.9 0.03*
S bilirubin  mg/dL 2.1 ± 1.7 1.9 ± 1.6 0.79
S albumin g/dL 2.2 ± 0,46 2.2 ± 0.5 0.62
Prothrombin time 14.9 ± 2.44 15.0 ± 1.9 0.34
S.creatinine  mg/dL 1.3 ± 0.87 1.3 ± 0.9 0.40
S.  sodium    meq/L                                                134.1  ±  9.4 135.1  ±  9.6 0.15
S.  potassium    meq/L                                                4.3  ±  0.7 4.3  ±  0.7 0.99
Data are expressed as No (%) and mean ± SD * = Signiﬁ  cant
DISCUSSION
Therapeutic paracentesis of 6 liters or more of ascetic 
ﬂ  uid is a recommended option for the treatment of tense Nasr, et al.: Circulatory dysfunction in massive hepatic ascites
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developed PICD. This ﬁ  gure is higher than reported by 
other studies using plasma expanders. It has been reported 
that PICD occurs in 80% of patients not receiving plasma 
expenders.[33] This might be attributed to the fact that 
over 70% of our patients received Dextran 70 as a plasma 
expander and only less than 30% received Salt Free Human 
Albumin (SFHA). PICD developed in 88% of those who 
received Dextran and only 38% of those who received 
SFHA This is in congruence with the ﬁ  nding of Planas et 
al, 1990,[34] Gines, et al, 1996[24] and Sola- Vera et al, 2003,[35] 
who found that the incidence of PICD was nearly double in 
patients receiving Dextran 70 6% compared with those who 
received SFHA (51% - 33% Vs 18% - 11%). An inverse 
relationship between the incidence of PICD and the half- 
life of the plasma expander used (days for Dextran- 70, and 
weeks for salt free human albumin) has been reported.[21] 
Although there was no signiﬁ  cant difference in the mean 
volume of ascetic ﬂ  uid removed between the 2 groups, the 
fact that our attempt to reach near total paracentesis, has led 
to the evacuation of 8 liters or more in all our patients with 
a mean of about 10 liters which might have contributed to 
the high incidence of PICD in this study.[35] This study had 
showed that albumin is more effective than saline in the 
prevention of PICD. Saline is a valid alternative to albumin 
when less than 6 L of ascitic ﬂ  uid is evacuated.
By univariate analysis, only age, presence of diabetes 
mellitus (DM), and the level of random blood glucose 
were signiﬁ  cantly different between those who developed 
PICD and those who did not. No other factors studied 
as predictors in this work whether demographic, clinical, 
laboratory orsonographic were found to be signiﬁ  cantly 
different. Interestingly, those who developed PICD were 
younger and DM was less frequent among them. However, 
the logistic regression model in this study has shown that the 
only two independent risk factors of PICD are younger age 
and the use of Dextran as expender. In the recent study of 
Sola- Vera et al, 2003, only the type of plasma expander out 
or refractory cirrhotic ascites. However, it has been linked 
with circulatory dysfunction associated with increased 
plasma rennin activity. This study was designed to assess 
the frequency and risk factors of parcentesis induced 
circulatory dysfunction (PICD) in our patients and to 
assess the haemodynamic and echocardigraphic changes 
associated with LVP and their relation with PICD. Forty 
ﬁ  ve patients with post-hapatic cirrhosis with Child Pugh 
grade C and massive or refractory ascites were subjected to 
LVP. The clinical, laboratory and ultrasonographic ﬁ  ndings 
of the study group are quite typical of this category of 
patients. 
All of the patients experienced marked relief of the 
abdominal distension following the LVP and none 
developed serious complications in the form of SBP, sepsis, 
bleeding or increase in the grade of encephalopathy until 
discharge after one week at least. Procedure-associated risks 
have been reported to be low and include a 1% chance 
of signiﬁ  cant abdominal-wall hematoma, 0.01% chance 
of hemoperitoneum, and a 0.01% chance of iatrogenic 
infection related to paracentesis,[26,27] but none of these 
occurred in this study. Degricija et al, 2003[28] also reported 
no systemic or local complications after removal of 6 liters 
of ascetic ﬂ  uid in 50 patients. Several large randomized, 
controlled trials have shown that repeated large-volume 
paracentesis is safer and more effective for the treatment 
of tense ascites compared with larger-than-usual doses of 
diuretics.[29-31] Total paracentesis has also been shown to be 
as safe as repeated partial paracentesis and to shorten the 
period of hospitalization and may even be performed on 
an outpatient basis.[25] The fact that none of the patients 
who developed PICD had any complications attests that 
this disturbance is usually silent on the short term and so 
has been considered by some authors to be a “cosmetic 
disturbance”,[32] although it has been associated with a rapid 
recurrence of tense ascites and shorter survival.[24]
According to the definition 73.3% of the patients 
Table 6: Best ﬁ  tting stepwise logistic regression 
model for occurrences of circulatory dysfunction 
(dependant variable) and various personal and disease 
characteristics as independent variables
Variable Beta 
coefﬁ  cient
SE P 
value
OR with 95% CI
Age (Years)  -0.13 0.05 <0.02* 0.80<.88<.97
Plasma 
expander (Alb=), 
Dextran=1
3.08 1.01 <0.005* 3.01<21.79<157.58
Constant 5.83 2.59 <0.05*
*staitically signiﬁ  cant  Dependant variable: Circulatory dysfunction (1=yes, 
0=no) R-square: 0.51  Model Chi-Square: 19.21, P <0.0001 Variables entered 
and excluded: Diabetes, ALT, AST, Cardiac disease, Na, K, S Creatinine, mean BP, 
volume aspirated, US ﬁ  ndings and haemodynamic status at base line.
Table 7: The hemodynamic changes in the study 
patients at baseline and 48 hrs after LVP 
Baseline 48 hrs PP
Range Mean ± SD Range Mean ± SD
HR    (bpm)* 70-110 87.5 ± 8.3 75-120 95.5 ± 9.50
MAP (mmHg)* 65 -155 98.4  ± 20.8 68 -140 90.7 ± 14.4
COP  (L/M)* 4 -11.3 7.5 ± 1.9 4.5 -14.7 8.3 ± 2.3
SPR 13.12 10.93
EF %* 32 -77 58.7 ± 9.99 27 - 77 61.1 ± 11.6
EA ratio  0.5 -1.6 0.9 ± 0.3 0.5 - 1.6 0.9 ± 0.3
PAP  34 -90 31.7 ± 15.2 34 - 90 31.5 ± 13.7
PwT (cms) 0.8 -1.5 1.0 ± 0.2 0.8 – 1.5 1.0 ± 0.3
IVwT( cms) 0.6-1.6 1.0 ± 0 .2 0.6 – 1.6 1.0 ± 0 .2
* = Signiﬁ  cant: P < 0.05Nasr, et al.: Circulatory dysfunction in massive hepatic ascites
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of 28 variables including demographic, clinical data as well 
as liver and renal tests was found to have an independent 
predictive value for the development of PICD.[35] To the best 
of our knowledge no other study reported that age had an 
effect on PICD. The fact that younger age immerged as an 
independent predictor, merits further study of whether older 
age blunts the vasoactive response and hence protects against 
PICD. It has to be noted that age is a non modiﬁ  able risk 
factor since it is not possible to deny younger patients the 
beneﬁ  t of LVP if they need it. 
In this study, the echocardiographic ﬁ  ndings at base line 
has shown that the patients already had a hyperdynamic 
circulatory state as indicated by the higher heart rate and 
cardiac output and lower mean arterial blood pressure 
than normal. These findings are in agreement with 
several studies of cirrhotic patients with and without 
ascites,[36-38] and has been explained by several factors 
including: increased sympathetic nervous activity, increased 
blood volume (increased preload), and the presence of 
arteriovenous communications.[39-41]
Forty eight hours after LVP the hyperdynamic circulatory 
state was accentuated as seen by the signiﬁ  cant increase 
in HR and COP and signiﬁ  cant decrease in MAP. These 
ﬁ  ndings conﬁ  rm earlier reports of heamodynamic changes 
early after paracentesis[42,43] that have been considered to 
have a favorable effect on alleviating some symptoms 
that characterize cirrhotic patients with ascites.[44,32] These 
early haemodynamic changes have been explained by the 
dynamics of paracentesis itself (short duration and higher 
ﬂ  ow rate of paracentesis),[45,46] local abdominal mechanical 
factors,[47] or a reﬂ  ex of the stimulation of cardiac-volume 
receptors inhibiting sympathetic vasoconstrictive tone and 
renal release of rennin via an increase of cardiac volume.[42]
Our results show that the accentuation of the hyperdynamic 
circulation 48 hours after LVP occurred in both those who 
did and did not develop PICD although the extent of 
change of HR, COP and MAP was higher among those 
who developed PICD than those who did not. This is in 
accordance with the ﬁ  ndings of Ruiz del Arbol et al. who 
demonstrated a signiﬁ  cant inverse correlation between 
changes in systemic vascular resistance (SVR) and PRA on 
day 6 after ascites removal.[21] This ﬁ  nding strongly suggests 
that PICD could be caused by enhancement of peripheral 
arterial vasodilatation that characterize these patients.[47] 
Hence it has been suggested that the use of arteriolar 
vasoconstrictors as terilipressin[48,49] or noradrenaline,[50] 
could be useful in preventing this complication. 
The hemodynamic changes observed in this study would 
support the recent hypothesis that immediately after 
paracentesis, an effective hypovolaemia due to accentuation 
of arteriolar vasodilatation occurs. The origin of this 
vasodilatation is probably multifactorial and includes 
an abrupt decrease in intra abdominal Pressure, a reﬂ  ex 
mechanism via the increase in cardiac output and an 
increased release of nitric oxide, likely to be secondary to 
shear stress. In response to this vasodilatation, activation 
of the renin–angiotensin and sympathetic nervous systems 
takes place. Patients who are able to compensate for this 
vasodilatation in the ﬁ  rst few days after paracentesis will 
not develop PICD and the levels of PRA will return to 
Table 8: Comparison of hemodynamic changes between patients who did and did not develop PICD at base line and 
24 hrs post-paracentesis
Variable Baseline mean ± SD 48 hrs post paracentesis mean ± SD Before/After difference 
Mean ± SEM (P value)
PICD 
(n=33)
N0PICD
(n=12)
P value PICD 
(n=33)
N0 PICD 
(n=12)
P value PICD 
(n=33)
N0 PICD 
(n=12)
HR   ( bpm)
Range
85.8 ± 8.2
70.0 - 110.0
91.8 ± 6.6
82.0 - 110.0 0.03*
94.1 ± 8.9
82.0 - 120.0
98.8 ± 10.5
75.0 - 120.0
0.14 8.30 ± 0.97
(P=0.001)*
6.92 ± 1.57
(P=0.001)*
MAP (mmHg)
Range
98.5 ± 17.9
75.0 - 140.0
98.3 ±  23.7
65.0 - 155.0
0.98 89.6 ± 11.6
70.0 - 115.0
91.9 ± 18.3
68.0 - 140.0
0.63 -8.86  ± 2.60
(<0002)*
-6.42  ± 3.22
(0.071)
COP  (L/M0
Range
7.4 ± 1.8
4.0 - 11.3
7.7 ± 2.2
4.5 - 11.1 0.67
8.3 ± 2.0
4.5 - 11.9
8.6 ± 3.1
4.7 – 14.7
0.73 0.90 ± 0.22
(<0001)*
0.88 ± 0.37
(0.038)*
EF 
Range
59.6 ± 9.0
32.0 - 75.0
56.1 ± 12.0
40.0 - 77.0
0.30 62.7 ± 10.9
27.0 - 74.0
57.0 ± 12.4
40.0 - 77.0
0.14 3.11 ± 1.66
(0.071)
0.92 ± 1.23
(0.47)
E/A  ratio
Range
0.9 ± 0.2
0.5 -1.4
0.9 ± 0.3
0.7 - 1.6
0.93 0.9 ± 0.3
0.5 - 1.6
0.9 ± 0.3
0.7 - 1.6
0.87 -0.01 ± 0.02
(0.53)
0.004 ± 0.004
(0.34)
PAP 
Range
32.8 ± 14.8
15.0 - 90.0
31.4 ± 13.3
15.0 - 60.0
0.78 31.1 ± 13.2
15.0  -85.0
32.4 ± 15.0
15.0 - 63.0
0.78 -1.68 ±0.78
(0.039)
0.93 ±  1.20
(0.45)
PwT (cms)
Range
1.0 ± 0.2
0.8 - 1.5
1.1 ± 0.2
0.8   -1.4
0.29 1.0 ± 0.1
0.8  -1.5
1.0 ± 0.2
0.8 - 1.4
0.38 -0.007 ± 0.01
(0.71)
0.03 ± 0.03
(0.34)
IVwT (cms)
Range
1.0 ± 0.10.
0.6 - 1.2
1.1 ± 0.2
0.9 - 1.6
0.04* 0.9 ± 0.1
0.6 - 1.2
1.1 ± 0.2
0.9 - 1.6
0.03 -0.1 ± 0.02
(0.49)
0.02 ± 0.002
(0.63)
Data are expressed as mean ± SD  * =Signiﬁ  cantNasr, et al.: Circulatory dysfunction in massive hepatic ascites
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baseline. However, PICD will develop in those who are 
unable to compensate. The degree of hyporesponsiveness 
to vasoconstrictors could play an important role in this 
setting”.[32]
As regards the cardiac functional status at base line, there 
was evidence of left ventricular diastolic dysfunction as 
indicated by the signiﬁ  cantly reduced E/A ratio, but no 
evidence of ventricular systolic dysfunction as evidenced 
by the normal EF and ventricular wall thickness (PwT 
and IVwT). These ﬁ  ndings are similar to most other 
echocardiographic studies of cirrhotic ascetic patients 
that showed alteration in diastolic, but not systolic 
function.[42,50-53] In contrast other studies suggested 
both systolic and diastolic ventricular dysfunction in 
alcoholic,[54] and non alcoholic cirrhotic patients.[55,56] 
After 48 hours from LVP there was no change in the 
echocardiographic parameters of ventricular function 
from base line except a signiﬁ  cant marginal increase 
in EF within the normal range. The latter ﬁ  nding is in 
agreement with that of Pozzi et al, 1997 who reported 
that the ventricular ejection fraction in cirrhotic patients 
with tense ascites was somewhat less than the control 
and non ascitic patients, with tendency to increase after 
large volume paracentesis. However, our ﬁ  ndings are in 
contrast with their ﬁ  nding that removal of ascitic ﬂ  uid by 
large volume paracentesis reduces the A wave velocity and 
increases the E/A ratio in patients with tense ascites.[56] 
Consequently the functional cardic parameters before or 
after LVP in this study did not reﬂ  ect on the occurrence 
of PICD.[57] It is really conﬁ  rmed that ascites is a feature 
of advanced liver disease related to cirrhosis so it really 
important to recognize.
CONCLUSION
Large volume paracentesis has been found to be safe 
and effective in the treatment of cirrhotic patients with 
tense/refractory ascites. Salt free human albumin is the 
plasma expander of choice especially if at least 8 liters are 
evacuated. The ventricular diastolic faunction is alter in 
cirrhotic patients with tense ascites. This might represent 
an early compensated stage of cardiomyopathy, but was 
not affected by LVP and did not reﬂ  ect on the occurrence 
of PICD.
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